Biotech | January 22, 2022
Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
UCB plans to submit regulatory applications in Q3 2022
UCB plans to submit regulatory applications in Q3 2022
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
However, these won’t be available at the nearest chemist store soon
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Ram’s appointment follows the launch of the CDI India division in October 2021.
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
The company has 47 ANDA's pending approval with the U.S.FDA
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Subscribe To Our Newsletter & Stay Updated
